Intelligent Medical Objects, Inc.

Intelligent Medical Objects, Inc. is a US-based company that specializes in enhancing healthcare outcomes through innovative clinical data quality solutions utilizing advanced terminologies and artificial intelligence. Founded in 1994 and headquartered in Rosemont, US, Intelligent Medical Objects, Inc. focuses on clinical data quality.

The company has undergone strategic pivots to refine its service offerings. The current CEO is Ann Barnes, and the company has received funding through three deals, with the most recent deal occurring on March 31, 2022. IMO Health specializes in clinical data quality solutions designed to enhance healthcare outcomes through advanced terminologies and artificial intelligence. Their flagship products include IMO Core, which addresses surgical scheduling and operational efficiency; IMO Core Periop, which focuses on procedure documentation and coding; and IMO Precision Normalize and Sets, which offer data standardization and value set management.

These solutions cater to healthcare providers, health tech organizations, life sciences, and public health entities, enabling improved administrative coding accuracy, reduced claim denials, and optimized point-of-care data utilization. IMO Health's products are predominantly used in the United States, with a growing presence in international markets, facilitating seamless documentation and coding processes for healthcare professionals. IMO Health operates on a subscription-based revenue model, where healthcare organizations and tech providers pay for access to their suite of clinical data solutions. Subscriptions vary based on provider size and specific services, allowing tailored pricing.

Transactions typically involve annual or multi-year agreements, ensuring sustained partnerships that support ongoing data management needs. The company generates revenue primarily through direct sales to healthcare providers, health information exchanges, and other stakeholders, leveraging the essential role of accurate data in improving health outcomes. Following the acquisition of a majority stake by Thomas H. Lee Partners in March 2022, the investment will support IMO Health's product development and expansion of commercial relationships with hospitals and healthcare providers.

The company plans to enhance its product offerings and actively pursue new market opportunities, although specific product release dates and targeted geographic regions have not been disclosed.